Aslan Fred sold $169K of ARTV

Aslan Fred (Chief Executive Officer) sold 23,463 shares of Artiva Biotherapeutics, Inc. (ARTV) at $7.20 ($0.17M total) on 2026-10-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Aslan Fred
Published Oct 7, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Bearish
high confidence
Mentioned
$ARTV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVBearishLow
01

Why it matters

The transaction is a primary disclosure but trivial in scale, offering limited trading insight.

02

Market read

Small insider sale with minimal market impact; primarily of interest to shareholders monitoring insider activity.

03

What to watch

The 10b5‑1 plan pre‑arranges sales, reducing the informational content of the transaction.

Relevance 3/10Novelty 3/10Timing: filed today

Background

Form 4 filings disclose insider transactions; this filing reports a modest CEO share sale under a pre‑arranged plan.

Company-level read

Ticker impact

$ARTVBearishHigh confidence
Context

CEO Aslan Fred sold 23,463 shares for $168,880 via a 10b5‑1 plan, reducing his stake to 1.52 million shares.

Expected impact

likely modest pressure as the market prices in the CEO's share reduction

Evidence & confidence

A 10b5‑1 sale by the chief executive signals personal liquidity needs; the amount ($169K) is small relative to market cap, so impact is limited but negative.

Market effects

None

None

None

Counterpoint

The sale may be routine and not reflect any negative outlook; investors could view it as a neutral liquidity event.

Key entities

  • Artiva Biotherapeutics, Inc.

    Biotech firm listed on Nasdaq under ticker ARTV.

  • Aslan Fred

    Chief Executive Officer of Artiva Biotherapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.